PL415351A1 - Sposób namnażania in vitro komórek T regulatorowych (Treg) - Google Patents

Sposób namnażania in vitro komórek T regulatorowych (Treg)

Info

Publication number
PL415351A1
PL415351A1 PL415351A PL41535115A PL415351A1 PL 415351 A1 PL415351 A1 PL 415351A1 PL 415351 A PL415351 A PL 415351A PL 41535115 A PL41535115 A PL 41535115A PL 415351 A1 PL415351 A1 PL 415351A1
Authority
PL
Poland
Prior art keywords
treg
cells
regulatory
vitro multiplication
multiplication
Prior art date
Application number
PL415351A
Other languages
English (en)
Other versions
PL236046B1 (pl
Inventor
Natalia Marek-Trzonkowska
Piotr Trzonkowski
Małgorzata Myśliwiec
Original Assignee
Gdański Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny filed Critical Gdański Uniwersytet Medyczny
Priority to PL415351A priority Critical patent/PL236046B1/pl
Priority to US16/063,144 priority patent/US11072779B2/en
Priority to EP16834056.0A priority patent/EP3402877A1/en
Priority to PCT/PL2016/000152 priority patent/WO2017105265A1/en
Publication of PL415351A1 publication Critical patent/PL415351A1/pl
Publication of PL236046B1 publication Critical patent/PL236046B1/pl
Priority to US17/381,192 priority patent/US20210348126A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Przedmiotem zgłoszenia jest nowy sposób namnażania in wtro komórek Treg CD4+CD25HighCD127-/LowFoxP3+, gdzie: proces namnażania komórek Treg odbywa się przez cały czas lub okresowo w temperaturze poniżej 37°C, optymalnie w temperaturze 33°C, wyizolowane komórki Treg namnaża się w pożywce SCGM lub X-vivo-20 suplementowanej ludzką surowicą lub płodową surowicą bydlęcą, do hodowli dodawane są mikrosfery magnetyczne opłaszczone przeciwciałami anty-CD3 i anty-CD28 w stosunku 1 : 1 (komórka: mikrosfera) oraz interleukina 2.
PL415351A 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+ PL236046B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL415351A PL236046B1 (pl) 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+
US16/063,144 US11072779B2 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory T cells
EP16834056.0A EP3402877A1 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory t cells
PCT/PL2016/000152 WO2017105265A1 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory t cells
US17/381,192 US20210348126A1 (en) 2015-12-17 2021-07-21 Method for ex vivo expansion of regulatory t cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL415351A PL236046B1 (pl) 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+

Publications (2)

Publication Number Publication Date
PL415351A1 true PL415351A1 (pl) 2017-06-19
PL236046B1 PL236046B1 (pl) 2020-11-30

Family

ID=57960799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL415351A PL236046B1 (pl) 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+

Country Status (4)

Country Link
US (1) US11072779B2 (pl)
EP (1) EP3402877A1 (pl)
PL (1) PL236046B1 (pl)
WO (1) WO2017105265A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106885A1 (en) 2016-12-07 2018-06-14 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
PL241050B1 (pl) * 2019-12-12 2022-07-25 Gdanski Univ Medyczny Zastosowanie limfocytów T regulatorowych jako leku w leczeniu stwardnienia rozsianego
CN113564117B (zh) * 2021-08-23 2023-12-26 山东省齐鲁干细胞工程有限公司 一种冻存脐带血来源调节性t细胞体外扩增优化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186207A1 (en) * 2004-01-08 2005-08-25 The Regents Of The University Of California Regulatory T cells suppress autoimmunity
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
CN102459577B (zh) 2009-05-18 2014-08-20 特拉科斯有限公司 适合临床应用于免疫介导性疾病的、具有增强型抑制功能的调节性t细胞的体外扩增方法
WO2013050596A1 (en) 2011-10-06 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of maintaining foxp3 expression in expanded t regulatory cell
WO2013109759A1 (en) * 2012-01-17 2013-07-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
PL218400B1 (pl) 2012-06-06 2014-11-28 Gdański Univ Medyczny Szczepionka do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnażania komórek Treg in vitro do wytwarzania szczepionki do leczenia cukrzycy typu 1

Also Published As

Publication number Publication date
EP3402877A1 (en) 2018-11-21
PL236046B1 (pl) 2020-11-30
WO2017105265A1 (en) 2017-06-22
US11072779B2 (en) 2021-07-27
US20180362928A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
Putnam et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation
Elkord et al. Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP
Chellappa et al. Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer
Strauss et al. Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with rapamycin
MX2020008327A (es) Metodos para preparar celulas t.
Zhou et al. Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations
MX2022009849A (es) Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
ZA201905822B (en) Antibodies against pd-l1
Ukena et al. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity
Parodi et al. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes
MX2022012196A (es) Metodos para cultivar celulas y kits y aparatos para ello.
MX2019011570A (es) Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
WO2018097540A3 (ko) 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
MA40253A (fr) Cellules modifiées pour thérapie cellulaire adoptive
WO2017011804A8 (en) Engineered cells for adoptive cell therapy
EP4289944A3 (en) Method for preparing genetically-modified t cells which express chimeric antigen receptor
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
MY189819A (en) Genetically modified cells and uses thereof
DiSpirito et al. Histone acetylation at the single-cell level: a marker of memory CD8+ T cell differentiation and functionality
Yu et al. IL-12 induced the generation of IL-21-and IFN-γ-co-expressing poly-functional CD4+ T cells from human naive CD4+ T cells
Kobyzeva et al. CD56dimCD57− NKG2C+ NK cells retaining proliferative potential are possible precursors of CD57+ NKG2C+ memory-like NK cells
Sun et al. Foxp3 is critical for human natural CD4+ CD25+ regulatory T cells to suppress alloimmune response
Lu et al. iTreg induced from CD39+ naive T cells demonstrate enhanced proliferate and suppressive ability
PL415351A1 (pl) Sposób namnażania in vitro komórek T regulatorowych (Treg)